ATRA
Atara Biotherapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 10 FDA decision: PDUFA: ATRA, tab-cel in Epstein-Barr virus positive post-t…
- Jan 13 ▼ Canaccord Genuity downgrades
- Jan 21 ▼ Freedom Broker downgrades
- Mar 2 ▼ 2 insiders sell $25.9K at $5.08
- Mar 3 Atara Biotherapeutics announced that its partner Pierre Fabre Pharma…
- May 7 ▲ 1 insider buy $4.7M at $9.35
- May 7 ▼ 1 insider sell $3.2M at $10.10
- May 8 ▲ Canaccord Genuity upgrades
- May 18 ▲ Freedom Broker upgrades
- May 18 ▼ 2 insiders sell $69.9K at $9.13
- Aug 17 ▼ 1 insider sell $40.9K at $8.08
- Sep 4 ▲ 1 insider buy $1000.0K at $9.60
Signal stack
Where each data set points today.
- InsidersMIXED
2 insiders bought $5.7M at an average $9.39. 3 insiders sold $3.3M. Price is 32% below their cost.
- InstitutionsMIXED
Q3 2026: 4 added (0 new), 3 trimmed or exited.
- Short sellersCOVERING
Short interest −15.3% to 296.7K shares. 13.4 days to cover, ≈3.0% of shares.
- TrendDOWNTREND
28% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $176.4K |
| Vanguard Global Advisers, LLC | DOUBLED | $39.6K |
| JONES FINANCIAL COMPANIES LLLP | TRIM | $2.7K |
| BARCLAYS PLC | TRIM | $1.8K |
| CITIGROUP INC | NEAR_EXIT | $9.00 |
| Point72 Asset Management, L.P. | DOUBLED | $7.9M |
| MACKENZIE FINANCIAL CORP | TRIM | $2.7M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $494.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2026Price is below the lowest target. Median implies +103%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| May 18, 2026 | Freedom Broker UPGRADE | Hold |
| May 8, 2026 | Canaccord Genuity UPGRADE | Buy |
| Jan 21, 2026 | Freedom Broker DOWNGRADE | Sell |
| Jan 13, 2026 | Canaccord Genuity DOWNGRADE | Hold |
| Dec 19, 2025 | Canaccord Genuity MAINTAIN | Buy |
| Mar 11, 2025 | Canaccord Genuity MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Cherry Brian N Director Sep 4, 2026 | BUY | $1000.0K |
Nguyen AnhCo President and CEO Aug 17, 2026 | SELL | $40.9K |
Redmile Group, LLC Director Jul 22, 2026 | EXERCISE | 195,211 sh |
Redmile Group, LLC Director Jul 22, 2026 | EXERCISE | 55,387 sh |
Redmile Group, LLC Director Jul 22, 2026 | TAX W/H | 60 sh |
Redmile Group, LLC Director Jul 22, 2026 | EXERCISE | 101,089 sh |
Redmile Group, LLC Director Jul 22, 2026 | EXERCISE | 38,735 sh |
Cherry Brian N Director Jun 11, 2026 | AWARD | 24,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 0 bullish · 1 bearish · 2 mixed · 8 neutral- BEARISH S-3Nov 10, 2026
Atara Biotherapeutics filed a replacement S-3 shelf registration statement covering up to $200M in…
The ATM facility gives Atara flexibility to raise capital opportunistically, but the company's history of frequent equity raises and negative book value suggest ongoing cash needs. The key catalyst…
- NEUTRAL 8-KNov 10, 2026
Atara reported Q3 2026 revenue of $1.2M (down 65% YoY from $3.5M, due to a one-time prior-year…
The March 31, 2027 PDUFA date for tab-cel is the primary value catalyst. Monitor FDA advisory committee activity and any pre-approval inspection outcomes. The $31M milestone would nearly double the…
- NEUTRAL 8-KJun 26, 2026
Atara Biotherapeutics disclosed the departure of Chief Accounting Officer Yanina Grant-Huerta…
The interim CFO appointment is a temporary measure; monitor for search for a permanent CFO and any further executive departures. The CAO departure is not a red flag alone, but the lack of a…
- NEUTRAL 3Jun 15, 2026
Brian N. Cherry filed a Form 3 initial statement of beneficial ownership, reporting 38,320 shares…
This is a routine initial ownership filing with no trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Cherry that could indicate insider conviction.
All ATRA filing & press-release reports (11)
- S-3 reportNov 10, 2026
- 8-K reportNov 10, 2026
- 8-K reportJun 26, 2026
- 3 reportJun 15, 2026
- CLUSTER reportMay 7, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 24, 2026
- S-3 reportMar 17, 2026
- 8-K reportMar 12, 2026
- CLUSTER reportMar 2, 2026
- 8-K reportMar 3, 2026